These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17279547)

  • 1. Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.
    Osorio A; Milne RL; Honrado E; Barroso A; Diez O; Salazar R; de la Hoya M; Vega A; Benítez J
    Hum Mutat; 2007 May; 28(5):477-85. PubMed ID: 17279547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
    Chenevix-Trench G; Healey S; Lakhani S; Waring P; Cummings M; Brinkworth R; Deffenbaugh AM; Burbidge LA; Pruss D; Judkins T; Scholl T; Bekessy A; Marsh A; Lovelock P; Wong M; Tesoriero A; Renard H; Southey M; Hopper JL; Yannoukakos K; Brown M; Easton D; Tavtigian SV; Goldgar D; Spurdle AB;
    Cancer Res; 2006 Feb; 66(4):2019-27. PubMed ID: 16489001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families.
    Maillet P; Chappuis PO; Khoshbeen-Boudal M; Sciretta V; Sappino AP;
    Cancer Genet Cytogenet; 2006 Aug; 169(1):62-8. PubMed ID: 16875939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
    Spurdle AB; Lakhani SR; Healey S; Parry S; Da Silva LM; Brinkworth R; Hopper JL; Brown MA; Babikyan D; Chenevix-Trench G; Tavtigian SV; Goldgar DE;
    J Clin Oncol; 2008 Apr; 26(10):1657-63. PubMed ID: 18375895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
    Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
    Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
    Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
    Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy.
    Malacrida S; Agata S; Callegaro M; Casella C; Barana D; Scaini MC; Manoukian S; Oliani C; Radice P; Barile M; Menin C; D'Andrea E; Montagna M
    J Clin Oncol; 2008 Jan; 26(1):26-31. PubMed ID: 18165637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
    García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
    Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
    Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
    Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.
    Mirkovic N; Marti-Renom MA; Weber BL; Sali A; Monteiro AN
    Cancer Res; 2004 Jun; 64(11):3790-7. PubMed ID: 15172985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and in silico analysis of BRCA1 and BRCA2 variants.
    Tommasi S; Pilato B; Pinto R; Monaco A; Bruno M; Campana M; Digennaro M; Schittulli F; Lacalamita R; Paradiso A
    Mutat Res; 2008 Sep; 644(1-2):64-70. PubMed ID: 18694767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum and incidence of BRCA1 pathogenic mutations in Slovak breast/ovarian cancer families.
    Konecny M; Vizvaryova M; Weismanova E; Ilencikova D; Mlkva I; Weismann P; Machackova G; Kausitz J
    Neoplasma; 2007; 54(2):137-42. PubMed ID: 17319787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
    Caligo MA; Bonatti F; Guidugli L; Aretini P; Galli A
    Hum Mutat; 2009 Jan; 30(1):123-33. PubMed ID: 18680205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
    Bonnet C; Krieger S; Vezain M; Rousselin A; Tournier I; Martins A; Berthet P; Chevrier A; Dugast C; Layet V; Rossi A; Lidereau R; Frébourg T; Hardouin A; Tosi M
    J Med Genet; 2008 Jul; 45(7):438-46. PubMed ID: 18424508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
    Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
    Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.
    Engert S; Wappenschmidt B; Betz B; Kast K; Kutsche M; Hellebrand H; Goecke TO; Kiechle M; Niederacher D; Schmutzler RK; Meindl A
    Hum Mutat; 2008 Jul; 29(7):948-58. PubMed ID: 18431737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.